Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
D.Western Therapeutics Institute ( (JP:4576) ) has shared an update.
D.Western Therapeutics Institute reported a 17.8% decline in net sales to ¥387 million for the year ended December 31, 2025, although its net loss narrowed to ¥632 million from ¥1,290 million a year earlier. The company’s equity ratio improved significantly from 43.9% to 66.1%, supported by a stronger net asset position and an increase in cash and cash equivalents to ¥1,709 million.
Operating cash outflows shrank compared with the prior year while financing cash inflows rose, indicating continued reliance on external funding to support R&D activities. For 2026, the company projects a further drop in net sales to ¥300 million and a deeper loss of ¥800 million, and it has again ruled out dividends, underscoring an ongoing investment phase and limited near-term returns for shareholders.
The most recent analyst rating on (JP:4576) stock is a Hold with a Yen98.00 price target. To see the full list of analyst forecasts on D.Western Therapeutics Institute stock, see the JP:4576 Stock Forecast page.
More about D.Western Therapeutics Institute
D.Western Therapeutics Institute, Inc. is a Tokyo-listed pharmaceutical research and development company focused on therapeutic drugs. The company operates under Japanese GAAP and targets niche therapeutic areas, generating relatively small but recurring licensing and royalty-based net sales in the domestic market and potentially abroad.
Average Trading Volume: 592,279
Technical Sentiment Signal: Sell
Current Market Cap: Yen5.53B
For an in-depth examination of 4576 stock, go to TipRanks’ Overview page.